Scandion Oncology announced that President Bo Rode Hansen by mutual agreement will leave his position with immediate effect. The process to identify a new permanent CEO has started. Bo Rode Hansen will also step down as a member of the Board of Directors of Scandion with immediate effect.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.608 SEK | -13.14% | -31.69% | -84.78% |
May. 22 | Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024 | |
May. 22 | Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-84.78% | 2.69M | |
+8.92% | 114B | |
+10.48% | 105B | |
-2.88% | 21.73B | |
-6.45% | 23.83B | |
-10.67% | 18.1B | |
-42.36% | 16.34B | |
-14.45% | 16.13B | |
+3.76% | 13.75B | |
+28.94% | 11.76B |
- Stock Market
- Equities
- SCOL Stock
- News Scandion Oncology A/S
- Scandion Oncology A/S Announces Board and Executive Changes